LOGIN  |  REGISTER
Recursion
Assertio

Electromed to Participate in Upcoming Investor Conferences

February 26, 2025 | Last Trade: US$18.93 0.24 -1.25

NEW PRAGUE, Minn. / Feb 26, 2025 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that management will participate in the following upcoming investor conferences:

The Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

  • Management will present at 10:30 a.m. Eastern Time on Tuesday, March 18, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. Interested parties may also access the live webcast here. Investors may request meetings through their Oppenheimer representative.

The Sidoti Virtual Small-Cap Conference

  • Management will present at 1:45 p.m. Eastern Time on Thursday, March 20, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page